TrialAnnals of surgery2013
Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial.
Ronald P DeMatteo et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
76 papers cite itlatest 60 shown
this paperpooled ittrialcites it